

**REGISTERED OFFICE**

**GRANULES INDIA LTD.,** 2nd Floor, 3rd Block, My Home Hub,  
Madhapur, Hyderabad - 500 081, Telangana, India.

Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com  
CIN: L24110TG1991PLC012471

**Dated: April 30, 2024**

To,  
National Stock Exchange of India Limited  
BSE Limited  
Symbol: NSE: GRANULES; BSE: 532482

**Sub: Press Release**

Dear Sir,

We are herewith enclosing the press release given by the Company.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours sincerely,

**For GRANULES INDIA LIMITED**

**CHAITANYA  
TUMMALA**

**CHAITANYA TUMMALA  
(COMPANY SECRETARY &  
COMPLIANCE OFFICER)**

Digitally signed by CHAITANYA TUMMALA  
DN: cn=, postalCode=500033, st=TELANGANA,  
street=2-2-186184 RAMAKRISHNA NAGAR, GOLDEN  
HARBINDRA AMBEREETHYVENKAT, HYDERABAD, o=Personal,  
serialNumber=cn=c0854c30785711e3f1a8a1f72da8346a265a  
56a8e23a0775c359  
pkcs10ym=+5615348b1843791ab44a627a756  
2.5.4.230-26f55d4e0755d6d17d78b0d09e2f547113311663a855  
07c26c02b1da0f5, email=CHAITANYA.TC@GMAIL.COM,  
cn=CHAITANYA TUMMALA  
Date: 2024.04.30 10:21:42 +05'30'





**Press Release**

**For Immediate Release**

## **Granules India Limited Announced ANDA Approval for Colchicine Capsules**

**Hyderabad, 30 April 2024:** Granules India Limited announced today that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA), filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the Company, for Colchicine Capsules, 0.6 mg. It is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Mitigare Capsules, 0.6 mg of Hikma International Pharmaceuticals LLC (Hikma).

Colchicine Capsules are indicated for prophylaxis of gout flares in adults.

Granules now have a total of 64 ANDA approvals from the US FDA (63 Final approvals and 1 tentative approvals).

The current annual U.S. market for Colchicine Capsules is approximately \$55 Million, according to MAT Feb 2024, IQVIA/IMS Health.

\*\*\*END\*\*\*



## **About Granules India Ltd. (BSE: 532482, NSE: GRANULES)**

Granules India Limited, incorporated in 1991 is a vertically integrated fast-growing Indian pharmaceutical company headquartered in Hyderabad with best-in-class facilities and a commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of the entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, U.S., and U.K. The Company has 10 manufacturing facilities out of which 8 are located in India and 2 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

**Safe Harbor:** This document is to provide general background information about the Company's activities as at the date of the release. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein. This release may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. No part of this release may be reproduced, quoted or circulated without prior written approval from Granules India Limited.

### **Media Contact:**

Priyanka Chawla  
Manager- Corporate Communications  
[priyanka.chawla@granulesindia.com](mailto:priyanka.chawla@granulesindia.com)

### **Investors Contact:**

**Chaitanya Tummala**  
Company Secretary  
040-69043614  
[chaitanya.tummala@granulesindia.com](mailto:chaitanya.tummala@granulesindia.com)